Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes

Diabetic Medicine : a Journal of the British Diabetic Association
L SibalP D Home

Abstract

Although the limitations of the Friedewald-calculated serum low-density lipoprotein cholesterol (LDL-C) are well recognized, many diabetes and lipid guidelines propose LDL-C as a therapeutic target. The validity of calculated LDL-C in people with Type 1 diabetes (T1DM) is uncertain and the use of alternatives such as non-high-density lipoprotein cholesterol (non-HDL-C) or apolipoprotein measurement unexplored. We have therefore measured LDL-C with the designated reference method and examined some of the potential sources of such bias, including plasma concentrations of other lipids and apolipoproteins. Seventy-four people with T1DM and 80 healthy control subjects were recruited. Fasting samples were collected for analysis of lipid profiles by a beta-quantification (BQ) reference method and by routine laboratory methods including direct HDL-C and calculation of LDL-C using the Friedewald formula. Overall, Friedewald LDL-C was 0.29 +/- 0.02 (mean +/- SE) mmol/l (P < 0.001) lower in the two groups than by the BQ method. This resulted in misclassification of approximately 50% of people with a calculated LDL-C < 2.0 mmol/l. Overestimation of HDL-C by the routine assay [0.08 +/- 0.01 mmol/l (P < 0.001)] accounted for approximately 28...Continue Reading

References

Dec 1, 1990·Baillière's Clinical Endocrinology and Metabolism·M R Taskinen
Jan 13, 1989·Clinica Chimica Acta; International Journal of Clinical Chemistry·P H WinocourP N Durrington
Jan 1, 1997·The American Journal of Medicine·S HiranyI Jialal
Jul 4, 2001·Clinical Chemistry and Laboratory Medicine : CCLM·H ScharnaglW März
Nov 29, 2001·Clinical Science·R J StevensUNKNOWN United Kingdom Prospective Diabetes Study (UKPDS) Group
Jun 6, 2003·The New England Journal of Medicine·David M NathanUNKNOWN Epidemiology of Diabetes Interventions and Complications Research Group
Oct 27, 2006·Diabetes Care·Trevor J OrchardRichard W Nesto
Jan 10, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Jan 18, 2008·Journal of Clinical Laboratory Analysis·Pornpen SrisawasdiMartin H Kroll

❮ Previous
Next ❯

Citations

Oct 27, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·C HeroK Eeg-Olofsson
Jun 11, 2015·The American Journal of Cardiology·Jeffrey W MeeusenAmy K Saenger
Sep 7, 2016·Journal of Atherosclerosis and Thrombosis·Hideto ChaenMitsuru Ohishi
Sep 11, 2014·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Ester Yeoh Chai KhengS Tavintharan
Apr 28, 2010·Nature Reviews. Endocrinology·Allan SnidermanJacqueline de Graaf
Jul 9, 2016·Current Opinion in Lipidology·Jeffrey W MeeusenAllan S Jaffe
Jun 25, 2014·Nature Reviews. Cardiology·Razvan T Dadu, Christie M Ballantyne
Jun 3, 2017·American Journal of Clinical Pathology·Stephen M RoperSridevi Devaraj
Jun 26, 2012·Expert Opinion on Pharmacotherapy·Eduard Montanya
Feb 2, 2019·Reviews on Recent Clinical Trials·Seyedeh Ameneh MotalebiFatemeh Mohammadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.